AstraZeneca's Zomig is top triptan in Europe
Anglo-Swedish drug major AstraZeneca has reported that its Zomig (zolmitriptan) has taken over from sumatriptan as the most-prescribed triptan (5-HT 1B/1D agonist) in the top five European markets. The Zomig formulations - Zomig Nasal Spray, Zomig Rapimelt and Zomig oral tablets - provide fast-acting and reliably effective migraine treatments to suit most patient needs and preferences, says the company.
According to IMS Health MIDAS data, the total monthly prescriptions for Zomig in the top five European markets (France, Germany, Italy, Spain and the UK cumulatively) are consistently more than those for sumatriptan. Since its first European launch in 1997, nearly 10 million prescriptions for Zomig have been written, notes AstraZeneca.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze